How much CJC-1295 per day?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds CJC-1295 (no DAC) and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
The review by Dominikowski and colleagues lists forum-reported use of CJC-1295 without DAC at 100 to 200 mcg per injection, 1 to 2 times daily, which it says is not clinical guidance; a DailyMed search found no US label, and the review says no controlled clinical study has directly evaluated that form in humans.12
The guide's example
100 mcg of CJC-1295 (no DAC) from a 10 mg vial mixed with 2 mL is 2 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 5 mg22% set up12 | 5 mg/mL: 100 mcg is 2 units, 200 mcg is 4 units, 250 mcg is 5 units | 2.5 mg/mL: 100 mcg is 4 units, 200 mcg is 8 units, 250 mcg is 10 units | 1.667 mg/mL: 100 mcg is 6 units, 200 mcg is 12 units, 250 mcg is 15 units |
| 10 mg67% set up12 | 10 mg/mL: 100 mcg is 1 unit, 200 mcg is 2 units, 250 mcg is 2.5 units | 5 mg/mL: 100 mcg is 2 units, 200 mcg is 4 units, 250 mcg is 5 units | 3.333 mg/mL: 100 mcg is 3 units, 200 mcg is 6 units, 250 mcg is 7.5 units |
Most often logged by Milligram users: 100 mcg, 33% logged.12
Vial strengths, water and units
Of the people who logged CJC-1295 no DAC, 67% set up a 10 mg vial and 22% a 5 mg vial.12
In the worked example, 100 mcg from a 10 mg vial mixed with 2 mL is 2 units on a U-100 syringe.3 That mix is the one most often logged in Milligram, set up by 31% of people, and 100 mcg is the dose most often logged, at 33%.12
100 mcg of CJC-1295 (no DAC) from a 10 mg vial mixed with 2 mL is 2 units on a U-100 syringe.
31% set up 10 mg + 2 mL12
Of the people who logged a dose unit, 73% logged mcg, 14% mg and 12% IU.12 The review and the trials give CJC-1295 doses in µg or microg/kg, not IU; the guide to HGH dosage in IU covers HGH, a different compound.14 The CJC-1295 no DAC calculator and the mixing guide cover other vials and doses.
Doses reported and logged
The review's dose table gives, for CJC-1295 without DAC, 100 to 200 mcg per injection under the skin, 1 to 2 times daily.1 The review takes this from forum reports, not a trial, and presents it as a description of unregulated self-administration, not clinical guidance.1 Among people who logged doses in Milligram, 33% logged 100 mcg, 17% 200 mcg and 14% 250 mcg.12
The published human trials, by Teichman and colleagues and Ionescu and Frohman, gave the long-acting, albumin-binding form, which the review calls CJC-1295 with DAC, and dosed by body weight.145 The review says that, to date, no controlled clinical studies have directly evaluated the no DAC form in humans.1
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Teichman and colleagues (two trials)4 | CJC-1295 or placebo under the skin: one of four ascending single doses, or two or three weekly or biweekly doses; relatively well tolerated, particularly at 30 or 60 microg/kg | Healthy adults aged 21 to 61; number not stated | 28 and 49 days |
| Ionescu and Frohman5 | One injection of 60 or 90 microg/kg; no significant difference between the two doses | Healthy men aged 20 to 40; number not stated | Sampled overnight before and 1 week after the injection |
| NCT00267527 (ConjuChem phase 2, terminated; form not stated)6 | Low dose, high dose or placebo; no dose figures in the record | 120 adults aged 18 to 65 with HIV-associated visceral obesity | 12 weeks, 6 weeks follow-up |
How often and for how long
The review's forum-derived cycles for CJC-1295 without DAC are 12 to 16 weeks on, then 4 to 6 weeks off.1 No label or human trial states a maximum duration; NCT00267527, the only study a ClinicalTrials.gov search for CJC-1295 returned, was registered with a 12-week treatment period.76
Label and regulators
A DailyMed search for cjc-1295 returned no labels.2 The review states that neither CJC-1295 variant is approved as a therapeutic agent by major regulators such as the FDA or EMA.1 The FDA places CJC-1295 in category 2 of bulk drug substances for compounding that may present significant safety risks; it says it has identified serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited.8 Australia's TGA names it as an example of an unapproved peptide product.9 For comparison, the Egrifta SV label gives tesamorelin, a different GHRH analogue, a dose of 1.4 mg injected subcutaneously once daily; the tesamorelin guide covers it.10
Storage after mixing
The Hospira bacteriostatic water label says the water is indicated only for diluting or dissolving drugs according to the drug manufacturer's instructions, and not to store reconstituted solutions unless the manufacturer directs otherwise.11 CJC-1295 has no US label, so there is no manufacturer direction to quote.2
Frequently asked questions
Where is CJC-1295 without DAC injected?
The review's table lists the route of CJC-1295 without DAC as not reported by any peer-reviewed human study.1 The review's forum-derived dose table lists it under the skin, and the Teichman trials of the long-acting form gave it under the skin.14 Of the people who logged a route, 99% logged under the skin.12 No CJC-1295 source states an injection site.
Where are CJC-1295 with ipamorelin and the other growth hormone peptides covered?
The CJC-1295 and ipamorelin guide, the CJC-1295 no DAC page and the growth hormone peptides page cover the rest.
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Frontiers in Endocrinology (Dominikowski et al.). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
- US National Library of Medicine, DailyMed. DailyMed label search for the name cjc-1295 (result: no labels). 2026. dailymed.nlm.nih.gov
- Eli Lilly and Company, via DailyMed. HUMULIN R (insulin human) injection, label (cited only for what U-100 means). 2026. dailymed.nlm.nih.gov
- Journal of Clinical Endocrinology and Metabolism (Teichman et al.), PubMed abstract. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. 2006. pubmed.ncbi.nlm.nih.gov
- Journal of Clinical Endocrinology and Metabolism (Ionescu and Frohman), PubMed abstract. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. 2006. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov, sponsor ConjuChem. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). 2006. clinicaltrials.gov
- ClinicalTrials.gov. ClinicalTrials.gov search for CJC-1295 (intervention search, and a second term search). 2026. clinicaltrials.gov
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026. fda.gov
- Therapeutic Goods Administration (Australia). Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. 2026. tga.gov.au
- Theratechnologies Inc., via DailyMed. EGRIFTA SV (tesamorelin) for injection, prescribing information (a different GHRH analogue, used for comparison only). 2026. dailymed.nlm.nih.gov
- Hospira, Inc., via DailyMed. Bacteriostatic Water for Injection, USP, label. 2026. dailymed.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted